Visual Impairment Clinical Trial
— TIL002Official title:
Post-market Study for At-home Evaluation of Near Visual Acuity With OdySight, a Smartphone Based Medical Application in Comparison to a Standardized Method (TIL002)
NCT number | NCT05510479 |
Other study ID # | 2020-A03583-36 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 5, 2021 |
Est. completion date | May 11, 2022 |
Verified date | August 2022 |
Source | Tilak Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
OdySight is a mobile application allowing self-testing of visual parameters including near visual acuity and communication of the data to an online dashboard to patient's doctors. TIL-002 post-market clinical trial objective is to evaluate the near visual acuity at home, measured with OdySight application in comparison to the standardized methods. The clinical trial is intended to prove that OdySight can provide relevant data and participate in the remote monitoring of subject vision.
Status | Completed |
Enrollment | 58 |
Est. completion date | May 11, 2022 |
Est. primary completion date | May 11, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: General inclusion criteria: 1. Age = 18 years, all genders 2. Affiliated to or beneficiary of the French health care system 3. Signed/written informed consent 4. Already user of Odysight on a compatible smartphone/tablet 5. Patients willing and able to comply with all study and follow-up procedure Ophthalmic inclusion criterion: 6. Baseline binocular visual acuity with habitual correction = 20/63 (3/10) AND with at least an eye = 20/200 (1/10). Exclusion Criteria: General exclusion criteria: 1. Any pathology that is considered by the investigator as capable of affecting the quality of the main evaluation criteria. 2. Any planned surgery likely to modify patient refraction during the study (cataract surgery for example) 3. Subject not considered by the investigator or designee to correctly use ODYSIGHT modules 4. Subject unable to recognize alphabet letters or unable to correctly distinguish body laterality 5. Not French speaking patient 6. Epileptic users |
Country | Name | City | State |
---|---|---|---|
France | Centre Ophtalmologique Rabelais | Lyon | |
France | Institut Ophtalmologique de l'Ouest Clinique Jules Verne | Nantes | |
France | Centre Hospitalier National d'Ophtahlomogie du Quinze-Vingts | Paris | Ile-de-France |
Lead Sponsor | Collaborator |
---|---|
Tilak Healthcare |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Near Visual Acuity - Subgroups analysis | To assess the equivalence between a smartphone based evaluation of near visual acuity with ODYSIGHT at home and with standardized methods in specific subgroups defined by visual acuity and by pathology | 2 months | |
Other | Near Visual Acuity variability | To assess variability of measurements with a smartphone-based evaluation of NVA with Odysight at home vs at clinic | 2 months | |
Other | Vision changes tracking | To evaluate ability of the VA application module to track vision change over time as compared to standardized methods. | 2 months | |
Other | Compliance to OdySight | To evaluate compliance of daily use among time. | 2 months | |
Primary | Equivalence between OdySight and standardized methods - Near Visual Acuity | To assess the equivalence between a smartphone based evaluation of near visual acuity with ODYSIGHT at home and standardized methods (Sloan ETDRS near vision letter chart and Landolt C near vision chart) performed in clinic. | 2 months | |
Secondary | Equivalence between OdySight and standardized methods - 4-meter distance Visual Acuity | ETDRS visual acuity at a 4-meter distance at clinic and near visual acuity evaluated with ODYSIGHT at home. | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT05619432 -
Re:Garde Program - Training and Maintaining Visual Perception in Older Adults
|
N/A | |
Completed |
NCT03670303 -
Trial of an Educational Intervention to Promote Spectacle Use Among Secondary School Children in Islamabad, Pakistan
|
N/A | |
Completed |
NCT02896738 -
MRI Screening for Auditory Pathway Malformations in Visually Impaired Children
|
||
Completed |
NCT01822717 -
Nonvisual Foot Inspection for People With Visual Imapirment
|
N/A | |
Completed |
NCT03865134 -
Evaluation of Visual - Motor Development in Children With Retinopathy of Prematurity
|
||
Active, not recruiting |
NCT04198350 -
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
|
N/A | |
Recruiting |
NCT05220449 -
Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery
|
N/A | |
Completed |
NCT04190147 -
Eye and Growth in Adolescents Born Moderate-to-late Preterm
|
||
Completed |
NCT05135195 -
A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training
|
N/A | |
Recruiting |
NCT05199363 -
Pediatric Patient Experience on a Diagnostic Path
|
N/A | |
Active, not recruiting |
NCT03767803 -
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
|
||
Recruiting |
NCT03571217 -
Shanghai Beixinjing Diabetic Eyes Study
|
||
Not yet recruiting |
NCT03726606 -
A Comparison of the Visual Performance of Trifocal Versus Extended Depth of Focus Intraocular Lenses
|
N/A | |
Completed |
NCT02259088 -
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
|
Phase 3 | |
Completed |
NCT06197607 -
Effect of Hand Exercises on Hand Grip Strength and Manual Ability in Children With Visual Impairment
|
N/A | |
Withdrawn |
NCT04579653 -
Pupillometry and Locus Coeruleus Activation (PuLCA)
|
N/A | |
Recruiting |
NCT05844982 -
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
|
Phase 3 | |
Recruiting |
NCT02258113 -
Measuring of Neuro-visual Functionality With Ocusweep
|
N/A | |
Completed |
NCT02607384 -
The Baltimore Reading and Eye Disease Study
|
N/A |